<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03960424</url>
  </required_header>
  <id_info>
    <org_study_id>AD-2017C3-9185</org_study_id>
    <nct_id>NCT03960424</nct_id>
  </id_info>
  <brief_title>Patient and Caregiver-Centered Diabetes Telemanagement Program for Hispanic/Latino Patients</brief_title>
  <official_title>Patient and Caregiver-Centered Diabetes Telemanagement Program for Hispanic/Latino Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare Diabetes Telemonitoring to comprehensive outpatient management (COM) on critical
      patient-centered outcomes, including HbA1c.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a multiphase mixed method,3 CER RCT to:

      Specific Aim 1: Assess usability of an evidence-based DTM intervention utilizing a CBPR
      approach1 and adapt it to facilitate acceptability and feasibility in a population of H/L
      patients with T2D, and their caregivers and providers.

      Specific Aim 2: Assess whether H/L patients receiving DTM attain significantly improved
      patient-centered outcomes compared to COM, through a CER RCT. Expected outcomes include
      improved diabetes QoL, GM, blood pressure (BP), cholesterol, medication adherence, and
      diabetes self-efficacy (SE), and reduced diabetes distress, problem areas in diabetes (PAID),
      inpatient utilization, unscheduled T2D physician visits and sick days.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Mixed Methods Design, incorporating adaptations before RCT trial commencement.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 months</time_frame>
    <description>Hemoglobin A1C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 months</time_frame>
    <description>Hemoglobin A1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia episodes</measure>
    <time_frame>6 months</time_frame>
    <description>Number of hypoglycemia episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>6 months</time_frame>
    <description>Morisky, Green, and Levine (MGL) Adherence Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes self-efficacy</measure>
    <time_frame>6 months</time_frame>
    <description>Diabetes Self-Efficacy Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAID</measure>
    <time_frame>6 months</time_frame>
    <description>Problem Areas in Diabetes Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>6 months</time_frame>
    <description>lbs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in cholesterol over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>BP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Diabetes-39 is a validated instrument specifically designed to measure quality of life for diabetes patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Diabetes Telemonitoring (DTM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for T2D, uses smart devices to share information between patients, caregivers, and clinicians. DTM includes:1) weekly real time &quot;virtual&quot; visit between patient and clinician 2) vital signs monitoring/interpretation 3) diabetes management 4) patient interactive educational videos and &quot;teach back&quot; quizzes, reinforcing self-management strategies 5) a caregiver app with supportive capability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comprehensive Outpatient Management (COM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comprehensive Outpatient Management (COM) is the most realistic evidence-based comparator, in that it is the most frequently recommended and used option for US T2D patients. COM, like DTM, is consistent with the 2018 ADA Standards which include, but are not limited to, past medical and family history, social history, medications, screening, physical examination, laboratory evaluation, etc.Patients are instructed to monitor blood glucose (within physician recommendations), and have routine or &quot;well&quot; visits every 3 months. Patients can set appointments with a T2D educator. COM patients will receive monthly calls from the study RN to collect data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comprehensive Outpatient Management</intervention_name>
    <description>Patients receiving comprehensive outpatient management experience typical care received in the outpatient setting.</description>
    <arm_group_label>Comprehensive Outpatient Management (COM)</arm_group_label>
    <other_name>COM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diabetes Telemonitoring</intervention_name>
    <description>Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for T2D, uses smart devices to share information between patients, caregivers, and clinicians.</description>
    <arm_group_label>Diabetes Telemonitoring (DTM)</arm_group_label>
    <other_name>DTM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hispanic patients with a diagnosis of diabetes

          -  Speaks English or Spanish

        Exclusion Criteria:

          -  Patient is not Hispanic

          -  Patient does not have a diagnosis of diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renee Pekmezaris, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Feinstein Institute for Medical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane Marbury, CRA</last_name>
    <phone>(516) 465-2776</phone>
    <email>dmarbury@northwell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Myia Williams, PhD</last_name>
    <phone>516-600-1485</phone>
    <email>mwilliam26@northwell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Feinstein Institute of Medical Research</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Renee Pekmezaris, PhD</last_name>
      <phone>516-600-1402</phone>
      <email>rpekmeza@northwell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Myia Williams, PhD</last_name>
      <phone>516-600-1485</phone>
      <email>mwilliam26@northwell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Renee Pekmezaris, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>July 18, 2019</last_update_submitted>
  <last_update_submitted_qc>July 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT03960424/Prot_SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT03960424/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

